What Are the Classifications of Myelodysplastic Syndromes?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Myelodysplastic syndromes are generally classified into “lower risk MDS” and “higher risk MDS.” Your physician can tell you which classification you fall under based on the characteristics of your disease. The three primary characteristics are percent of marrow blasts (immature cells), chromosome abnormalities, and blood counts (platelets, red cells, and white cells). 

In general, if you have blasts that are less than 10 percent of total blood cells, you fall in the lower risk category. Blasts equal to or above 10 percent, many abnormal chromosomes, and low platelet and red and white blood cell counts put you in the higher risk category. 

The most commonly used classification system is called the International Prognostic Scoring System (IPSS). The table below shows how your risk category correlates to the IPSS score. A score of 0 to 1 is in the lower risk category, whereas a score above 1 places you in the higher risk category. 

 

IPSS Risk 

Score 

Average Survival 

Low 

5-6 years 

Intermediate 1 

0.5-1 

3-4 years 

Intermediate 2 

1.5-2 

1-1.5 years 

High 

= 2.5 

4-6 months 

 

These categories help determine the type of treatment you will receive. 

 

This content was last reviewed August 15, 2010 by Dr. Reshma L. Mahtani.
Latest Cancer News
Most women with cancer want a role in decisions

February 9, 2012 — NEW YORK (Reuters Health) - About two-thirds of women diagnosed with early stage breast cancer want to take part in making decisions about their treatment, according to a new survey of patients from five different countries.

Cancer trial participants may have misconceptions

February 9, 2012 — NEW YORK (Reuters Health) - People enrolled in early stage trials for possible cancer treatments may underestimate the risks involved and overestimate the potential benefits, suggests a new study.

U.S. FDA sets draft rules for biotech drug copies

February 9, 2012 —

Select news items provided by Reuters Health